Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 9 sales; 244 institutions reported holding it in 13F filings for Q2 2026, worth $949.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.85M in total
- 9
- 13F holdersQ2 2026, +7 vs. previous quarter
- 244
- 13F valueReported value at the end of Q2 2026
- $949.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding XERS, Q2 2026
No superinvestor reported holding XERS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Xeris Biopharma Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 (view filing)6:21 PM ET | Sep 1 | Same day | McCulloch KevinSee Remarks | SSale | −15.0K | $8.49 | −$127.3K | −0.9%1.64M after | 10b5-1 |
| Sep 1, 2026 (view filing)6:21 PM ET | Sep 1 | Same day | Hecht BethSee Remarks | SSale | −16.7K | $8.49 | −$141.4K | −1.5%1.13M after | 10b5-1 |
| Sep 1, 2026 (view filing)6:20 PM ET | Sep 1 | Same day | Pieper StevenSee Remarks | SSale | −5.00K | $8.50 | −$42.5K | −0.4%1.36M after | 10b5-1 |
| Aug 12, 2026 (view filing)4:44 PM ET | Aug 12 | Same day | Pieper StevenSee Remarks | SSale | −5.00K | $8.50 | −$42.5K | −0.4%1.36M after | 10b5-1 |
| Aug 4, 2026 (view filing)5:30 PM ET | Aug 3 | 1 day | McCulloch KevinSee Remarks | SSale | −15.0K | $8.02 | −$120.2K | −0.9%1.68M after | 10b5-1 |
| Aug 4, 2026 (view filing)5:16 PM ET | Aug 3 | 1 day | Hecht BethSee Remarks | SSale | −16.7K | $8.01 | −$133.6K | −1.4%1.14M after | 10b5-1 |
| Jul 7, 2026 (view filing)5:11 PM ET | Jul 6-7 | 1 day | Pieper StevenSee Remarks | SSale | −45.0K | $8.52 | −$383.2K | −3.2%1.37M after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)4:40 PM ET | Jul 1 | 1 day | McCulloch KevinSee Remarks | SSale | −90.0K | $8.03 | −$722.5K | −5.1%1.69M after | 10b5-1 |
| Jul 2, 2026 (view filing)4:38 PM ET | Jul 1 | 1 day | Hecht BethSee Remarks | SSale | −16.7K | $8.03 | −$133.9K | −1.4%1.16M after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Persky MarlaDirector | SSale | −15.5K | $5.90 | −$91.5K | −10.9%126.5K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Xeris Biopharma Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,525,539 | $115.0M | 0.00% | +1,579,754+12.2% | Added |
| Capstone Investment Advisors, LLC | – | $62.6M | 0.44% | – | – |
| D. E. Shaw & Co., Inc. | 7,804,758 | $61.8M | 0.04% | +15,947+0.2% | Added |
| Vanguard Capital Management LLC | 7,340,229 | $58.1M | 0.00% | +359,347+5.1% | Added |
| State Street Corp | 4,821,566 | $38.2M | 0.00% | +163,392+3.5% | Added |
| Geode Capital Management, LLC | 4,718,183 | $37.4M | 0.00% | +427,554+10.0% | Added |
| Nuveen, LLC | 4,385,141 | $34.7M | 0.01% | +1,468,543+50.4% | Added |
| Polar Asset Management Partners Inc. | – | $28.8M | 0.53% | – | – |
| Rosalind Advisors, Inc. | 2,908,981 | $23.0M | 8.65% | −322,719−10.0% | Reduced |
| Qube Research & Technologies Ltd | 2,893,749 | $22.9M | 0.03% | −1,220,676−29.7% | Reduced |